Matches in Wikidata for { <http://www.wikidata.org/entity/Q82400236> ?p ?o ?g. }
Showing items 1 to 46 of
46
with 100 items per page.
- Q82400236 description "article scientifique (publié 2009)" @default.
- Q82400236 description "artikull shkencor i botuar më 01 janar 2009" @default.
- Q82400236 description "artículu científicu espublizáu en xineru de 2009" @default.
- Q82400236 description "im Jahr 2009 veröffentlichter wissenschaftlicher Artikel" @default.
- Q82400236 description "scientific article published on 01 January 2009" @default.
- Q82400236 description "wetenschappelijk artikel" @default.
- Q82400236 description "наукова стаття, опублікована в січні 2009" @default.
- Q82400236 description "գիտական հոդված հրատարակված 2009 թվականի հունվարի 1-ին" @default.
- Q82400236 name "Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, B" @default.
- Q82400236 name "Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, B" @default.
- Q82400236 name "Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, B" @default.
- Q82400236 type Item @default.
- Q82400236 label "Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, B" @default.
- Q82400236 label "Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, B" @default.
- Q82400236 label "Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, B" @default.
- Q82400236 prefLabel "Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, B" @default.
- Q82400236 prefLabel "Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, B" @default.
- Q82400236 prefLabel "Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, B" @default.
- Q82400236 P1433 Q82400236-16107383-E4EC-4C19-A3BC-FA6651DD757C @default.
- Q82400236 P1476 Q82400236-82ABEA4A-EF5B-48D1-B9C2-2C6322013F68 @default.
- Q82400236 P2093 Q82400236-7663EAA6-B49A-49BB-A254-2E31B6E6754F @default.
- Q82400236 P304 Q82400236-3686627A-A384-4E20-9546-6639213271BD @default.
- Q82400236 P31 Q82400236-5F3B0996-2E68-49E8-84D4-9B3719E82C59 @default.
- Q82400236 P356 Q82400236-373F7FCC-9D52-46BF-A975-DC1E43325A92 @default.
- Q82400236 P433 Q82400236-065557DB-6474-4F02-B964-5768691957DB @default.
- Q82400236 P478 Q82400236-F86B07FC-2521-4255-8DF1-2363A4186731 @default.
- Q82400236 P577 Q82400236-38B30275-7356-4010-A8C0-9C8A451899E2 @default.
- Q82400236 P698 Q82400236-6006C5BB-A0A1-4250-8F14-AEAC85ACA18A @default.
- Q82400236 P921 Q82400236-52F75C8C-B25C-4F40-AA64-0EF21B65FD72 @default.
- Q82400236 P921 Q82400236-F6CC2BCB-E7DE-4C01-BBC0-3AD4D86871CB @default.
- Q82400236 P921 Q82400236-F7E9B023-8ABC-4ED7-8993-881CA80037F8 @default.
- Q82400236 P356 J.EURURO.2008.09.035 @default.
- Q82400236 P698 20050017 @default.
- Q82400236 P1433 Q15763991 @default.
- Q82400236 P1476 "Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper C, Kaye S, Dearnaley D, Lee G, de Bono JS. J Clin Oncol 2008;26:4563-71" @default.
- Q82400236 P2093 "Mario A Eisenberger" @default.
- Q82400236 P304 "248" @default.
- Q82400236 P31 Q13442814 @default.
- Q82400236 P356 "10.1016/J.EURURO.2008.09.035" @default.
- Q82400236 P433 "1" @default.
- Q82400236 P478 "55" @default.
- Q82400236 P577 "2009-01-01T00:00:00Z" @default.
- Q82400236 P698 "20050017" @default.
- Q82400236 P921 Q181257 @default.
- Q82400236 P921 Q27888393 @default.
- Q82400236 P921 Q5452194 @default.